Literature DB >> 19031032

IFN-alpha in the generation of dendritic cells for cancer immunotherapy.

Stefano Maria Santini1, Caterina Lapenta, Laura Santodonato, Giuseppina D'Agostino, Filippo Belardelli, Maria Ferrantini.   

Abstract

Dendritic cells (DCs) play a crucial role in linking innate and adaptive immunity, by virtue of their unique ability to take up and process antigens in the peripheral blood and tissues and, upon migration to draining lymph nodes, to present antigen to resting lymphocytes. Notably, these DC functions are modulated by cytokines and chemokines controlling the activation and maturation of these cells, thus shaping the response towards either immunity or tolerance.An ensemble of recent studies have emphasized an important role of type I IFNs in the DC differentiation/activation, suggesting the existence of a natural alliance between these cytokines and DCs in linking innate and adaptive immunity. Herein, we will review how type I IFNs can promote the ex vivo differentiation of human DCs and orient DC functions towards the priming and expansion of protective antitumor immune responses. We will also discuss how the knowledge on type I IFN-DC interactions could be exploited for the design of more selective and effective strategies of cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19031032     DOI: 10.1007/978-3-540-71029-5_14

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  13 in total

1.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors:  Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

2.  Monocytes to functional dendritic cells is often a bridge too far for cancer therapy.

Authors:  William F Carson; Steven L Kunkel
Journal:  Transl Res       Date:  2011-05-13       Impact factor: 7.012

3.  Type I IFN gene delivery suppresses regulatory T cells within tumors.

Authors:  H Hashimoto; R Ueda; K Narumi; Y Heike; T Yoshida; K Aoki
Journal:  Cancer Gene Ther       Date:  2014-11-28       Impact factor: 5.987

Review 4.  Monocyte-derived DC maturation strategies and related pathways: a transcriptional view.

Authors:  Luciano Castiello; Marianna Sabatino; Ping Jin; Carol Clayberger; Francesco M Marincola; Alan M Krensky; David F Stroncek
Journal:  Cancer Immunol Immunother       Date:  2011-01-22       Impact factor: 6.968

Review 5.  Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant.

Authors:  Bo Jin; Tao Sun; Xiao-Hong Yu; Chao-Qun Liu; Ying-Xiang Yang; Ping Lu; Shan-Feng Fu; Hui-Bin Qiu; Anthony E T Yeo
Journal:  J Biomed Biotechnol       Date:  2010-07-05

6.  Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12.

Authors:  Stefano M Santini; Caterina Lapenta; Simona Donati; Francesca Spadaro; Filippo Belardelli; Maria Ferrantini
Journal:  PLoS One       Date:  2011-02-28       Impact factor: 3.240

7.  Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments.

Authors:  Eleonora Aricò; Luciano Castiello; Francesca Urbani; Paola Rizza; Monica C Panelli; Ena Wang; Francesco M Marincola; Filippo Belardelli
Journal:  J Transl Med       Date:  2011-05-17       Impact factor: 5.531

8.  Microfluidic systems to study tissue barriers to immunotherapy.

Authors:  Ann Ramirez; Mayowa Amosu; Priscilla Lee; Katharina Maisel
Journal:  Drug Deliv Transl Res       Date:  2021-07-03       Impact factor: 5.671

9.  IFN-α regulates Blimp-1 expression via miR-23a and miR-125b in both monocytes-derived DC and pDC.

Authors:  Stefania Parlato; Roberto Bruni; Paola Fragapane; Debora Salerno; Cinzia Marcantonio; Paola Borghi; Paola Tataseo; Anna Rita Ciccaglione; Carlo Presutti; Giulia Romagnoli; Irene Bozzoni; Filippo Belardelli; Lucia Gabriele
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

10.  Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.

Authors:  Kouichirou Aida; Reina Miyakawa; Koji Suzuki; Kenta Narumi; Takeshi Udagawa; Yuki Yamamoto; Tatsuya Chikaraishi; Teruhiko Yoshida; Kazunori Aoki
Journal:  Cancer Sci       Date:  2014-01-04       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.